Abstract 141P
Background
In antibody-mediated oncotherapy, IgG monoclonal antibodies have been the class of choice for the treatment of different cancers. However, tumour-antigen specific IgE antibodies are emerging as a new avenue for cancer therapy. This class of antibody have a high affinity for cognate Fcε receptors expressed on tumour-resident immune cells, such as macrophages and mast cells, and a lack of inhibitory Fc receptors, offering the chance to activate anti-tumour responses in tissues. Recently, a tolerable safety profile and anti-tumour efficacy of an IgE antibody recognizing the tumour-associated antigen, folate receptor α (FRα), has been shown in the first-in-class clinical trial of this agent.
Methods
We engineered a monoclonal IgE antibody, with human constant domains, recognising CSPG4 to target human melanoma. In vitro Fab-mediated antitumour effects, and mediated antibody-dependent cellular cytotoxicity (ADCC) against melanoma cells by immune effector cells were evaluated. CSPG4 antigen may be cleaved and released from the surface of tumour cells, and may bind to anti-CSPG4 antibodies, preventing them from engaging tumour cells and impairing their anti-tumour efficacy; or complexes of shed CSPG4 may cross-link anti-CSPG4 IgE engaged with basophils, which could potentiate degranulation and type I hypersensitivity. CSPG4 antigen shedding was measured in melanoma cell supernatant and in human sera. As an early evaluation of safety, we tested the propensity for CSPG4 IgE to induce RBL-SX38 degranulation in the presence of melanoma patient sera, and in unfractionated patient blood in basophil activation tests (BAT).
Results
CSPG4 IgE bound to melanoma tumours, induced Fab-mediated antitumour effects, and mediated ADCC against melanoma cells. We measured minimal shedding of the CSPG4 antigen in melanoma cell supernatants. Low levels of CSPG4 were detected in the circulation of melanoma patients and healthy subjects, with no significant difference in levels between the groups. CSPG4 IgE did not trigger RBL-SX38 degranulation and did not activate basophils in the BAT assay, suggesting lack of propensity to trigger anaphylaxis.
Conclusions
Our findings suggest that CSPG4 IgE may be an efficacious and safe immunotherapy for melanoma.
Legal entity responsible for the study
The authors.
Funding
Epsilogen Ltd.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
78P - Final Analysis of the French Real-World Study EVIDENS: Effectiveness, Safety & Quality of Life At 36 Months of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
Presenter: Fabrice Barlesi
Session: Poster Display
79P - A prospective, single-arm, phase II study to evaluate the efficacy and safety of Tislelizumab plus chemotherapy in resectable NSCLC
Presenter: Daqiang Sun
Session: Poster Display
80P - Efficacy and Safety of Tislelizumab Combined with Anlotinib and 2-cycles Chemotherapy as First-line Treatment for Advanced NSCLC(TISAL-FE-01)
Presenter: jun Tang
Session: Poster Display
81P - Real-World Experience with Docetaxel Regimens in Metastatic Non-Squamous (mNSq) Non-Small Cell Lung Cancer (NSCLC) Patients Previously Treated with Platinum-Based Chemotherapy (PCT) and an Immune Checkpoint Inhibitor (ICI) in the United States (US)
Presenter: Marisa Bittoni
Session: Poster Display
82P - The Role of Circadian Rhythms in NSCLC Immunotherapy Efficacy: A Focus on First Dose Timing
Presenter: Martin Igor Gomez-Randulfe Rodriguez
Session: Poster Display
84P - Adebrelimab plus chemotherapy (chemo) as first-line treatment for extensive-stage small-cell lung cancer (ES-SCLC): 3-year update of the phase 3 CAPSTONE-1 study
Presenter: Ying Cheng
Session: Poster Display
85P - Phase II trial of tislelizumab plus sitravatinib as maintenance therapy in extensive-stage small-cell lung cancer (ES-SCLC)
Presenter: Yun Fan
Session: Poster Display
86P - Durvalumab plus Olaparib as maintenance therapy in extensive-stage small-cell lung cancer (TRIDENT): updated efficacy and safety analysis
Presenter: Yan Huang
Session: Poster Display
88P - Adverse events (AEs) as potential predictive factors of activity in patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (AB)
Presenter: MARA PERSANO
Session: Poster Display